Is the RotaTeq Vaccine Cost Effective As We Rein In Healthcare Costs?
Posted May 14 2009 12:00am
By Kim Stagliano
As President Obama looks at revamping out of control health care costs in The United States, this study calls into question the cost of RotaTeq, Dr. Paul Offit's rotavirus vaccine (from Merck) which is on the AAP schedule as a routine vaccination.
Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI. Respiratory and Enteric Virus Branch, Mailstop A34, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30333, USA. firstname.lastname@example.org
OBJECTIVE: In February 2006, a safe, efficacious, orally administered pentavalent human-bovine reassortant rotavirus vaccine was licensed and recommended for routine immunization of all children in the United States. We assessed the health and economic impacts of a national rotavirus immunization program in the United States.